- Poly5225 (See other available formats)
- Regulatory Status
- Other Names
- VEGFA165, MVCD1, VEGF, Vascular permeability factor (VPF)
- Goat Polyclonal IgG
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Check Availability||Save|
VEGF (known also as VEGFA) was initially identified in conditioned medium from bovine pituitary follicular cells. VEGFA belongs to the VEGF family, which has the following members: VEGF-A, VEGF-B, VEGF-C (VEGF-2), VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs, such as T.f. (Trimeresurus flavoviridis) and svVEGF (called VEGF-F), have been described. VEGFA is alternatively spliced to generate variants with different numbers of amino acids, such as VEGFA121, VEGFA145, VEGFA165, and VEGFA189. VEGFA165 is predominant and responsible for VEGFA biological potency. While VEGF121 is freely diffusible and does not bind to neuropilins (NRPs) or heparan sulphate (HS), VEGF165 and VEGF189 bind to both, resulting in retention on the cell surface or in the extracellular matrix. NRP1 lacks a typical kinase domain and acts as a co-receptor, and in response to VEGF165, NRP1 couples with VEGF-Rs to signal in endothelial cells. In addition, it has been suggested that bone marrow cells that are recruited to Ewing’s tumors are differentiated into vascular smooth muscle cells, and VEGF165 is responsible for this differentiation. VEGFA is highly expressed in most of the solid tumors generated in breast, lung, renal, colorectal, and liver tissues. VEGFA has strong vascular permeability activity, and significantly contributes to the formation of ascites tumors. VEGFA can act as a direct proinflammatory mediator during the pathogenesis of rheumatoid arthritis (RA), and protect rheumatoid synoviocytes from apoptosis, which contributes to synovial hyperplasia. VEGFA is expressed in synovial macrophages and synovial fibroblasts in RA patients. Also, VEGFA is associated to age-related macular degeneration (AMD). AMD is due to neovascularization that originates from endothelial cells in the choroid that grow into neurosensory retina as choroidal neovascularization (CNV).Product Details
- Antibody Type
- Host Species
- Recombinant human VEGF-165
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is < 0.1 EU/µg of the protein (< 0.01 ng/µg of the protein) as determined by the LAL test.
- The LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- The antibody is bottled at the concentration indicated on the vial. Please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.
- Storage & Handling
- Upon receipt, store frozen at -20°C. Make small volume aliquots if needed and avoid repeated freeze-thaw cycles to prevent denaturing the antibody.
Block - Quality tested
WB - Verified
- Recommended Usage
Each lot of this antibody is quality control tested by blocking the binding of 10 ng/mL biotinylated recombinant human VEGF-165 to 1 µg/mL immobilized recombinant human VEGFR1 (Cat. No. 555804) ND50 range: 0.15 - 0.75 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
This antibody has not been tested for ICC.
Specificity: While Poly5225 was generated specifically against VEGF-165 and is quality tested against VEGF-165, it may demonstrate some cross-reactivity to other isoforms of VEGF.
- Product Citations
AB_2894616 (BioLegend Cat. No. 522505)
- VEGFA is a key player in vasculogenesis, the formation of blood vessels from progenitor cells, as well as angiogenesis. The expression of the VEGFA gene is upregulated via hypoxia, estrogen, and NF-κB pathways. In addition, VEGFA is upregulated by PDGF-BB, P1GF, TGFβ1, IGF1, FGFs, HGF, TNFα, and IL-1. VEGFA induces proliferation and cell migration in endothelial cells, and plays important roles during wound healing. Also, VEGFA regulates haematopoietic stem cell survival. VEGFA interacts with vascular endothelial cells and monocytes/macrophages, which express VEGFR1. This interaction induces proliferation of endothelial cells and stimulates migration of monocytes/macrophages. VEGFR2 is expressed in endothelial cells and VEGFR2-signaling is essential for the development of vascular systems in the embryo.
- Embryonic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells
- VEGFA binds and activates two tyrosine kinase receptors, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1)
- Antigen References
1. Conn G, 1990. 87:1323.
2. Gerber H, 2002. 417:954.
3. Shibuya M, 2006. 39:469.
4. Reddy K, 2008. 11:257.
5. Shibuya M 2008. 41:278.
6. Monaghan-Benson E, 2010. 177:2091.
7. Koch S and Claesson-Welsh L. 2012. . 2:a006502.
- Gene ID
- 7422 View all products for this Gene ID
- View information about VEGF-165 on UniProt.org
- Do you guarantee that your antibodies are totally pathogen free?
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.